Middle East & Africa Molecular Diagnostics Market
Middle East & Africa Molecular Diagnostics Market by Product & Service (Kits, Instruments), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS), Application [Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)] - Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Middle East & Africa molecular diagnostics market is projected to grow from USD 0.33 billion in 2026 to USD 0.47 billion by 2031, expanding at a growth rate of 7.5%. Market growth is supported by the increasing demand for accurate diagnostic solutions, particularly to address the region’s ongoing disease burden & diagnostic gaps. Gradual improvements in healthcare infrastructure, increased spending on diagnostic capabilities, and improved accessibility of molecular tests in major countries are favoring adoption at a steady pace. Furthermore, increased awareness regarding early disease diagnosis and improved laboratory infrastructure are aiding the growth of the market in the Middle East & Africa.
KEY TAKEAWAYS
-
By CountryBy country, Saudi Arabia held the largest share of the market in 2025.
-
By Product & ServiceBy product & service, the reagents & kits segment is expected to register the highest CAGR of 8.2% during the forecast period.
-
By Test TypeBy test type, the lab tests segment accounted for the largest share of 66.3% of the market in 2025.
-
By Sample TypeBy sample type, the blood, serum, and plasma segment accounted for the largest market share of 63.3% in 2025.
-
By TechnologyBy technology, the PCR segment accounted for the largest share of the market in 2025.
-
By ApplicationBy application, the oncology testing segment is expected to be the fastest-growing segment during the forecast period.
-
By TechniqueBy technique, multiplex testing accounted for the largest market share in 2025.
-
Clinical ApplicationBy clinical application, the diagnostics segment is expected to dominate the market.
-
By End UserBy end user, the diagnostic labs segment is expected to register the highest CAGR.
-
Competitive LandscapeDanaher (US), Roche (Switzerland), Illumina (US), bioMérieux (France), and Thermo Fisher Scientific (US) were identified as Star players in the Middle East & Africa molecular diagnostics market, which correspondingly are supported by their strong market presence and extensive product portfolios.
-
Competitive LandscapeVela Diagnostics (Singapore) and Savyon Diagnostics (Israel) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas.
Some of the major drivers of the Middle East & Africa molecular diagnostics market include the high burden of infectious diseases and the rising incidence of chronic conditions such as cancer, which are increasing the need for accurate diagnostic testing. Expanding healthcare access in several countries, supported by government-led health programs & investments, is enabling the broader use of molecular diagnostics. In addition, growing awareness of early diagnosis, the gradual modernization of laboratory infrastructure, and the increased adoption of advanced diagnostic technologies are contributing to sustained market growth across the region.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Middle East & Africa molecular diagnostics market is undergoing a gradual change as healthcare systems work to strengthen diagnostic capacities and improve testing access. A key trend is the increasing adoption of molecular diagnostics within public health programs, particularly to support disease surveillance & early detection initiatives. The expansion of labs and the gradual uptake of automated and high-throughput molecular platforms are also shaping testing practices. At the same time, disruption is emerging through the introduction of compact and PoC molecular systems, which are helping to extend testing to remote and resource-limited settings.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Increasing incidence of infectious diseases and cancers
-
Rise in technological advancements
Level
-
High cost of molecular diagnostic equipment
-
Inadequate reimbursements
Level
-
Increasing importance of companion diagnostics
-
Rising usage of automation solutions to enhance laboratory productivity
Level
-
Operational barriers
-
Evolving regulatory requirements
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing incidence of infectious diseases and cancers
The key factors contributing to the demand for molecular diagnostics include the increasing burden of infectious diseases & the rising incidence of cancer in the Middle East & Africa. There is a growing trend toward the use of accurate and timely molecular testing to support early detection, disease monitoring, and treatment decision-making. Molecular diagnostics products are being adopted as healthcare systems place greater focus on improving diagnostic accuracy in an attempt to deal with complex disease patterns and improve patient outcomes.
Restraint: High cost of molecular diagnostic equipment
The high costs associated with molecular diagnostic instruments remain a major restraint in the region. The expense of acquiring advanced platforms, along with ongoing costs for maintenance and consumables, can limit adoption, particularly in resource-constrained settings. Budget limitations in public healthcare systems further slow large-scale deployment of molecular diagnostics across some markets.
Opportunity: Increasing importance of companion diagnostics
The growing use of targeted therapies is creating opportunities for companion diagnostics in the Middle East & Africa. Molecular tests that help identify suitable patient populations are gaining relevance, especially in oncology care. As precision medicine approaches gradually expand, the demand for companion diagnostics is expected to rise, opening new avenues for molecular testing applications.
Challenge: Operational barriers
Operational challenges also remain factors that may limit the efficient use of molecular diagnosis in the region. The absence of laboratory infrastructure, differences in test standards, and a shortage of experts may influence laboratory workflow efficiency and test consistency. Addressing these operational constraints will be important to support the broader & more reliable adoption of molecular diagnostic solutions.
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Application of rapid PCR-based molecular platforms for high-throughput infectious disease testing & decentralized diagnostic workflows. | Supports faster test turnaround, improves scalability, and enables efficient deployment across diverse testing environments. |
 |
Integrated molecular diagnostic systems for infectious disease testing, cancer diagnostics, and companion diagnostics in centralized labs. | Delivers high test accuracy, standardized results, and seamless integration across laboratory workflows. |
 |
MDx solutions for rapid identification of pathogens & monitoring of healthcare-associated infections (HAIs). | Enables timely detection, supports infection control strategies, and improves disease management outcomes. |
 |
Use of next-generation sequencing technologies for oncology profiling, genetic analysis, and large-scale genomic testing programs. | Delivers deep genomic insights, supports precision medicine strategies, and enables scalable high-throughput analysis. |
 |
Application of comprehensive molecular diagnostic instruments and assays for infectious disease testing, genetic analysis, and oncology diagnostics. | Supports high test accuracy, scalable testing workflows, and reliable performance across a wide range of applications. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Middle East & Africa molecular diagnostics ecosystem consists of key stakeholders and components across the entire value chain, including products & services, test types, sample types, technologies, applications, techniques, clinical applications, and end users. The stakeholders include manufacturers engaged in developing and introducing products, distributors who sell via third parties or e-commerce platforms, and R&D partners offering outsourced development and manufacturing support. End users include hospitals & clinics, diagnostic laboratories, and other end users that apply molecular diagnostics solutions in carrying out diagnostics. These constitute the key stakeholders in the Middle East & Africa molecular diagnostics supply chain.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Middle East & Africa Molecular Diagnostics Market, By Product & Service
By product & service, the market is segmented into reagents & kits, instruments, and services & software. In 2025, the reagents & kits segment accounted for the largest market share, primarily due to their recurring use in every molecular diagnostic test and strong demand across a broad range of applications. High testing volumes, continuous assay consumption, and regular launches of upgraded kits to meet evolving diagnostic needs also support the segment’s leading position.
Middle East & Africa Molecular Diagnostics Market, By Test Type
By test type, the market is segmented into lab tests and PoC tests. In 2025, the lab tests segment held the largest market share, driven by its widespread use for complex and high-volume molecular testing. Lab-based testing supports a broad range of applications, including infectious disease detection, oncology, and genetic testing. It also allows for higher throughput and standardized workflows. The availability of advanced instrumentation and the ability to handle large sample volumes contribute to the dominant position of lab tests.
Middle East & Africa Molecular Diagnostics Market, By Sample Type
By sample type, the market is segmented into blood, serum, and plasma; urine; and other sample types. In 2025, the blood, serum, and plasma segment accounted for the largest market share, as these specimens are most commonly used for a wide range of applications. Their compatibility with multiple molecular technologies, reliable biomarker availability, and routine use in clinical testing support high sample volumes and consistent demand, contributing to the segment’s leading position.
Middle East & Africa Molecular Diagnostics Market, By Technology
By technology, the market is segmented into PCR, isothermal nucleic acid amplification technology, DNA sequencing & NGS, in situ hybridization, DNA microarrays, and other technologies. In 2025, PCR accounted for the largest market share, driven by its broad use across routine molecular diagnostic applications. PCR remains widely adopted due to its high sensitivity, reliability, and ability to deliver rapid results across infectious disease testing, cancer, and genetic testing.
Middle East & Africa Molecular Diagnostics Market, By Application
By application, the market is segmented into genetic testing, oncology testing, infectious disease diagnostics, and other applications. In 2025, the infectious disease diagnostics segment dominated the market, driven by high testing volumes for a wide range of viral & bacterial infections. The continued need for timely & accurate pathogen detection, routine monitoring, and disease surveillance supports a strong demand for molecular tests in this segment.
Middle East & Africa Molecular Diagnostics Market, By Technique
By technique, the market is segmented into multiplex testing and singleplex testing. In 2025, multiplex testing accounted for the largest market share, driven by its ability to detect multiple targets from a single sample in one run. This approach improves testing efficiency, reduces sample & reagent usage, and supports higher throughput.
Middle East & Africa Molecular Diagnostics Market, By Clinical Application
By clinical application, the market is segmented into diagnostics and screening. In 2025, the diagnostics segment held the largest market share, driven by the strong demand for confirmatory and disease-specific molecular tests used in clinical decision-making.
Middle East & Africa Molecular Diagnostics Market, By End User
By end user, the market is segmented into hospitals & clinics, diagnostic laboratories, and other end users. In 2025, diagnostic laboratories accounted for the largest market share, driven by their high testing volumes and capability to handle complex molecular assays.
REGION
Saudi Arabia is expected to register the highest CAGR in Middle East & Africa molecular diagnostics market
Saudi Arabia emerged as the fastest-growing country within the region due to continuous government investments in healthcare modernization & diagnostic infrastructure. The expansion of advanced laboratory facilities and the increasing adoption of molecular testing technologies have facilitated a faster uptake. In addition, national health initiatives focused on early diagnosis have contributed to stronger growth.
MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
Danaher (Star) is a leading player in the Middle East & Africa molecular diagnostics market due to its strong portfolio of well-established molecular testing platforms supported by continuous innovation & automation. The company benefits from broad assay menus and scalable systems, which drive recurring demand for consumables. Additionally, Danaher’s focus on workflow efficiency, test reliability, and strategic acquisitions has enabled it to maintain a strong competitive position across key MDx applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 0.32 Billion |
| Market Forecast in 2031 (Value) | USD 0.47 Billion |
| Growth Rate | CAGR of 7.5% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2024 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | Middle East (Saudi Arabia, UAE, Qatar, Kuwait, Egypt, Oman, Rest of Middle) and Africa |
WHAT IS IN IT FOR YOU: MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Product matrix, which provides a detailed comparison of the product portfolio of each company in the Middle East & Africa molecular diagnostics market | Enables easy comparison of competitors’ offerings, helping identify gaps, overlaps, and differentiation opportunities |
| Company Information | Additional five company profiles of players operating in the Middle East & Africa molecular diagnostics market | Provides insights into competitors’ strategies, innovation focus, and partnerships, supporting strategic planning |
RECENT DEVELOPMENTS
- December 2024: The Federal Government of Nigeria entered into an agreement with Abbott Laboratories GmbH (Germany), Siemens Healthineers AG (Germany), and its Nigerian partner Tanit Medical Engineering. The agreement aims to enhance healthcare access and expand diagnostic capacity across Nigeria through improved medical and diagnostic infrastructure.
- October 2024: Illumina (US) launched its MiSeq i100 Series of sequencing systems, delivering unparalleled benchtop speed and simplicity to advance next-generation sequencing (NGS) for labs.
- September 2024: Roche (Switzerland) launched the cobas Respiratory flex test. The assay is the first diagnostic test to incorporate Roche’s proprietary TAGS (Temperature-activated Generation of Signal) technology, which combines multiplex polymerase chain reaction (PCR) with color, temperature control, and advanced data processing. The test enables the detection of up to 15 respiratory pathogens from a single PCR run.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
The study involved major activities in estimating the current market size for the global Middle East & Africa Molecular Diagnostics Market. Exhaustive secondary research was done to collect information on the Middle East & Africa Molecular Diagnostics Market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the Middle East & Africa Molecular Diagnostics Market.
The four steps involved in estimating the market size are as follows:
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to, to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources mainly include industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.
Market Size Estimation
The top-down and bottom-up approaches were used to estimate and validate the Middle East & Africa Molecular Diagnostics Market’s total size. These methods were also used extensively to estimate the size of various subsegments in the market.
- The key players in the industry have been identified through extensive secondary research.
- Primary and secondary research have determined the revenues generated by leading players operating in the Middle East & Africa Molecular Diagnostics Market.
- All percentage share, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses an individual’s genetic makeup to identify a predisposition to any particular disease or condition and diagnose it.
Stakeholders
- Senior Management
- End Users
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global Middle East & Africa Molecular Diagnostics Market by product & service, test type, sample type, technology, application, technique, clinical application, end user, and region
- To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall Middle East & Africa Molecular Diagnostics Market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market with respect to five regions, namely North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments, such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the Middle East & Africa Molecular Diagnostics Market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
- To study the impact of AI/Gen AI on the Middle East & Africa Molecular Diagnostics Market, along with the macroeconomic outlook for each region.
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Middle East & Africa Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Middle East & Africa Molecular Diagnostics Market